GABA transport inhibitor, showing selectivity for GAT-3 and GAT-2 (IC50 values are 5, 21 and 388 μM for hGAT-3, rGAT-2 and hGAT-1 respectively). Increases thalamic GABA levels and is an anticonvulsant following systemic administration in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 505.61. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.98 mL||9.89 mL||19.78 mL|
|5 mM||0.4 mL||1.98 mL||3.96 mL|
|10 mM||0.2 mL||0.99 mL||1.98 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the biological activity of the product.
Borden et al (1994) Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptors Channels 2 207 PMID: 7874447
Borden (1996) GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem.Int. 29 335 PMID: 8939442
Dalby (2000) GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 39 2399 PMID: 10974324
If you know of a relevant reference for (S)-SNAP 5114, please let us know.
View Related Products by Product Action
Keywords: (S)-SNAP 5114, (S)-SNAP 5114 supplier, GABA, reuptake, inhibitors, inhibits, BGT-1, GAT-2, GAT-3, Transporters, Monoamine, Neurotransmitter, (S)-SNAP5114, 1561, Tocris Bioscience
5 Citations for (S)-SNAP 5114
Citations are publications that use Tocris products. Selected citations for (S)-SNAP 5114 include:
Kersanté et al (2013) A functional role for both -aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus. J Neurophysiol 591 2429 PMID: 23381899
Patel et al (2016) Context-Dependent Modulation of GABAAR-Mediated Tonic Currents. J Physiol 36 607 PMID: 26758848
Kékesi et al (2015) Recurrent seizure-like events are associated with coupled astroglial synchronization. J Neurosci 9 215 PMID: 26150770
Kinney (2005) GAT-3 transporters regulate inhibition in the neocortex. Mol Pain 94 4533 PMID: 16135550
Herd et al (2013) Extrasynaptic GABA(A) receptors couple presynaptic activity to postsynaptic inhibition in the somatosensory thalamus. J Neurosci 33 14850 PMID: 24027285
Do you know of a great paper that uses (S)-SNAP 5114 from Tocris? Please let us know.
Reviews for (S)-SNAP 5114
There are currently no reviews for this product. Be the first to review (S)-SNAP 5114 and earn rewards!
Have you used (S)-SNAP 5114?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.